PRESS RELEASE | PORCHEVILLE, FRANCE – March 14, 2024
GENEVOLUTION launched a new in vitro DPRA test under GLP to Enhance Consumer Safety
GENEVOLUTION, a leader in the field of product safety research and development, is proud to announce the launch of its new in vitro Direct Peptide Reactivity Assay (DPRA) for assessing skin sensitization. This breakthrough marks a significant advancement in our commitment to alternative methods to ensure product safety for consumers.
GenEvolutioN is proud to introduce the Direct Peptide Reactivity Assay (DPRA), a cutting-edge testing method designed to mimic the biochemical mechanisms of human skin and accurately predict the sensitizing potential of chemical substances. By measuring the reactivity of small molecules with peptides containing cysteine or lysine residues, the DPRA simulates the key molecular interactions involved in allergic skin reactions, offering a scientifically advanced, ethical alternative to traditional animal testing.
The DPRA test is fully aligned with international regulatory guidelines, including recommendations from the OECD (Organisation for Economic Co-operation and Development) for alternative methods to animal testing. Its adoption underscores GenEvolutioN’s commitment to scientific innovation, regulatory compliance, and consumer safety.
By integrating the DPRA into preclinical safety assessments, manufacturers in the cosmetics, pharmaceutical, and chemical industries gain access to a reliable, reproducible, and animal-free solution for evaluating product safety. This pioneering approach not only meets evolving industry standards but also responds to the growing demand for cruelty-free testing solutions from both regulators and consumers.
Further strengthening its position as an industry leader, GenEvolutioN is the official distributor in France of Senzagen’s GARD™skin (Genomic Allergen Rapid Detection). This genomic-based technology analyses the expression of specific genes associated with allergic responses in human monocyte cell lines, providing an enhanced prediction model for skin sensitization. In combination with DPRA, these technologies form part of an Integrated Testing Strategy (ITS) to further improve accuracy in allergen detection.
“Our commitment to responsible innovation and consumer safety has led us to develop the DPRA test, a breakthrough in alternative testing methods,” says Isabelle Mouche, co-founder and CEO of GenEvolutioN. “This technology not only enhances trust in product safety but also sets a new benchmark for ethical, high-performance safety assessments.”
